CEO David-Bejker

Fri, Jun 03, 2022 11:15 CET

Medium resolution

Original resolution

Subscribe

Related Releases

Affibody and Chiesi Group collaborate to develop and commercialize innovative treatments for respiratory diseases Tue, Mar 07, 2023 10:23 CET

Affibody Announce Positive Additional Izokibep Phase 2 Data in Patients with Psoriatic Arthritis (PsA) will be Presented at American College of Rheumatology (ACR) Convergence 2022 Tue, Nov 08, 2022 17:07 CET

Affibody, ACELYRIN, and Inmagene Bio Announce Positive Results from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis Tue, May 03, 2022 16:18 CET